Summary
Senior leaders from STS and the American Association for Thoracic Surgery discuss the concerns that informed the decision not to endorse the 2021 Guideline for Coronary Artery Revascularization published in December by the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions. Concerns discussed include: the devaluation of both coronary artery bypass grafting (CABG) as a treatment option and the evidence supporting bypass surgery as a preferred approach in select high-risk patient populations, and the superior long-term benefits of CABG versus percutaneous coronary intervention in decreasing repeat reintervention.
Panelists:
John H. Calhoon, MD
STS President
The University of Texas Health Science Center at San Antonio
San Antonio, TX
Leonard N. Girardi, MD
Director, AATS Board
NewYork-Presbyterian/Weill Cornell Medical Center
New York, NY
Shaf Keshavjee, MD, MSc, FRCSC
AATS President
University of Toronto
Toronto, ON, Canada
Thomas E. MacGillivray, MD
STS First Vice President
Houston Methodist
Houston, TX
Joseph F. Sabik III, MD
STS Secretary (2017-2022)
University Hospitals Cleveland Medical Center
Cleveland, OH
Lars G. Svensson, MD, PhD
AATS Vice President
Cleveland Clinic
Cleveland, OH